ellaOne
Description: Emergency contraceptive pill with ulipristal acetate (UPA).
Product Details
User: Female
Hormonal: Yes
Delivery Method: Oral
Duration Type: Emergency
Duration: Single use
Regimen: - Single tablet taken up to 5 days after unprotected intercourse
- Single tablet taken up to 5 days after unprotected intercourse
Dose: 30 mg
Active Pharmaceutical Ingredient (API): - ulipristal acetate
- ulipristal acetate
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: HRA Pharma
Project Phase: Limited Market Availability
Development Stage: SRA/WHO PQ Approved
Active Development: Yes
Status Details: - ellaOne was approved for use throughout the European Union by the European Medicines Agency (EMA) in 2009. Approved by the US FDA in 2010.
- Product is marketed in over 60 countries.
- ellaOne was approved for use throughout the European Union by the European Medicines Agency (EMA) in 2009. Approved by the US FDA in 2010.
- Product is marketed in over 60 countries.
Additional Information
References: HRA Pharma website: http://www.hra-pharma.com/index.php/en/our_products/womens_health
Gemzell-Danielsson, K. Meng C. (2010). Emergency contraception: potential role of ulipristal acetate. International Journal of Women's Health. 2:53-61.
HRA Pharma website: http://www.hra-pharma.com/index.php/en/our_products/womens_health
Gemzell-Danielsson, K. Meng C. (2010). Emergency contraception: potential role of ulipristal acetate. International Journal of Women's Health. 2:53-61.